ALBUQUERQUE, N.M. , Oct.
28, 2024 /PRNewswire/ -- T-Neuro Pharma, a leading biotechnology company dedicated to developing innovative therapies for neurodegenerative diseases, announced today that it will present new research on its T-Track blood biomarker assay for Alzheimer's at the upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference. The poster presentation, scheduled for Oct. 31 in Madrid, Spain , will showcase the company's progress in expanding the applicability of its innovative diagnostic tool.
The presentation, "Levels of age-related CD8 T cells binding HLA track with Alzheimer's disease status in HLA-A2+ and HLA-A2- patients: expansion of a flow cytometric blood biomarker assay to all patients," will be presented by Christopher Wheeler , Ph.D., CSO of T-Neuro Pharma.
Key Findings: The original T-Track assay, which detects changes in blood T cells corresponding to AD by counting T cells recognizing a specific peptide+HLA-A2, has been limited to patients expressing HLA-A2. New research assessed whether T-Track could be expanded to HLA-A2-negative patients by counting T cells that recognized HLA irrespective of peptide and A2 subtype. Results showed that even with lower levels of T cells bound to HLA in HLA-A2-negative patients, their binding corresponds with AD status with similar accuracy as the original assay.
This breakthrough provides a foundation for expanding T-Track to all patients, including minorities with proportionally more HLA-A2-negative indi.